Core Viewpoint - Shanghai Mengke Pharmaceutical Co., Ltd. is projected to incur a loss of 240 million yuan in 2025, with only one product, Kangtaizuoan tablets, commercialized since its IPO in August 2022, and has yet to achieve annual profitability [1][2] Financial Performance - In 2025, the company reported total revenue of 141.77 million yuan, an increase of 8.83% year-on-year; however, it recorded a net loss attributable to shareholders of 241.61 million yuan and a net loss of 250.27 million yuan after excluding non-recurring gains and losses [1] - Revenue for the years 2022 to 2024 was 48.21 million yuan, 90.78 million yuan, and 130 million yuan respectively, with net losses of 220 million yuan, 420 million yuan, and 440 million yuan [2] Product Development and Market Strategy - The company has only one product, Kangtaizuoan, in the commercialization stage, while other products remain in preclinical or clinical research phases [2] - In September 2025, the company initiated a capital operation plan to issue shares to Nanjing Haiqing Pharmaceutical Co., Ltd. for 1.032 billion yuan, which would result in a change of control, with Haiqing holding 20% of the shares [3] - A strategic cooperation agreement was signed with Haiqing to leverage existing market resources for deeper commercialization of products, with sales revenue targets set for 2026-2028 at 260 million yuan, 388 million yuan, and 600 million yuan respectively [3] Challenges and Future Plans - The planned capital operation was halted in November 2025 due to disagreements with major shareholder Genie Pharma, leading the company to explore alternative financing channels [4] - Concerns regarding liquidity have arisen, prompting inquiries from investors about the company's cash flow and future financing plans [4] - The company reported a significant reduction in expense ratios in Q3 2025, with R&D expense ratio down by 59.84 percentage points and sales expense ratio down by 26.34 percentage points, attributed to strict cost control measures [5]

Core Viewpoint - Yunding Xinyao announced the approval of its new drug, Weishiping (Arginine Acumod Tablets), for the treatment of moderate to severe active ulcerative colitis in adults who have insufficient response to traditional therapies or biologics [1] Group 1: Drug Approval and Clinical Trials - The approval is based on the results of the ENLIGHTUC study, a multi-center Phase III registration clinical trial in Asia, and the global Phase III registration study ELEVATEUC [1] - The ENLIGHTUC study included 340 patients and achieved statistical significance with good safety profiles during treatment [1] Group 2: Commercialization and Strategic Goals - The company is preparing for the commercialization of Weishiping and aims to expedite its availability to domestic patients while pushing for inclusion in the national medical insurance catalog [1] - This approval is a key component of the company's 2030 development strategy, which emphasizes a dual approach of "BD cooperation + self-research" to achieve both commercialization and R&D value [1] - The company plans to exceed 10 billion RMB in revenue by 2028 and over 15 billion RMB by 2030, with a projected annual compound growth rate of over 50% from 2025 to 2030 [1]

Core Viewpoint - The approval of the new drug, Weishiping, by the National Medical Products Administration of China marks a significant milestone for the company, aimed at treating moderate to severe active ulcerative colitis in adults who have inadequate response to traditional therapies or biologics [1] Group 1: Drug Approval and Clinical Trials - The approval is based on the results of the ENLIGHTUC study, a multicenter Phase III clinical trial in Asia involving 340 patients, which demonstrated statistical significance and good safety profiles for Weishiping [1] - The global Phase III study, ELEVATEUC, also contributed to the approval process, indicating robust clinical evidence supporting the drug's efficacy [1] Group 2: Commercialization and Strategic Goals - The company plans to actively prepare for the commercialization of Weishiping, aiming to make the therapy available to domestic patients as soon as possible and to push for its inclusion in the national medical insurance catalog [1] - This approval is a key component of the company's 2030 development strategy, which emphasizes a dual approach of "BD cooperation + self-research" to achieve both commercialization and research value [1] - The company targets to exceed 10 billion RMB in revenue by 2028 and over 15 billion RMB by 2030, with an expected compound annual growth rate of over 50% from 2025 to 2030 [1]

Core Viewpoint - The collaboration between Rongchang Biologics and AbbVie is viewed positively, with significant financial implications for Rongchang Biologics, including a $650 million upfront payment and potential milestone payments totaling up to $4.95 billion [1] Group 1: Financial Implications - Rongchang Biologics' stock rose nearly 4%, currently trading at HKD 92.3, with a trading volume of HKD 206 million [1] - The collaboration includes a two-digit tiered royalty on net sales outside Greater China, enhancing revenue potential [1] - UBS upgraded Rongchang Biologics' rating from "Neutral" to "Buy," raising the target price from HKD 63.8 to HKD 120 [1] Group 2: Strategic Outlook - The partnership is expected to facilitate global expansion of RC148 in research and commercialization, leveraging AbbVie's multinational capabilities [1] - UBS holds a positive view on the differentiated development strategy for RC148, anticipating that the upfront payment will improve Rongchang Biologics' net debt situation [1] - The company is projected to achieve breakeven by 2026, supported by multiple new drug approvals [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Vigonvita Life Sciences Co., Ltd. 蘇州旺山旺水生物醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2630） 自願公告 與先聲藥業就氫溴酸氘瑞米德韋(VV116)新適應症訂立許可協議 本公告由蘇州旺山旺水生物醫藥股份有限公司（「本公司」或「旺山旺水」）自願作 出，以告知本公司股東及潛在投資者本集團最新業務發展狀況。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司與先聲藥業集團有限公司 （「先聲藥業」）就VV116新適應症訂立許可協議（「該協議」）。根據該協議，本公司 將授予先聲藥業VV116在大中華區抗呼吸道合胞病毒（「RSV」）感染以及抗人偏肺 病毒（「HMPV」）感染適應症的獨家許可權益。旺山旺水與先聲藥業強強聯合，發 揮各自研發、生產及商業化的優勢，加速VV116的臨床開發和商業化進程，以期 惠及更多患者。 關於VV116 VV1 ...

Core Insights - The company is preparing for a busy 6 to 9 months ahead, focusing on key clinical developments and transitions [2] Group 1: Clinical Developments - The company plans to bring MAPT, its first CNS drug administered via subcutaneous injection, to the clinic [2] - Following MAPT, the company will introduce its first dimer, the PCSK9 APOC3 dimer, which is expected to be a significant tool against atherosclerotic cardiovascular disease (ASCVD) [2] Group 2: Regulatory and Data Milestones - A major event is the PDUFA date for plozasiran in November, marking a transition from an R&D-only company to one that is also commercial [3] - The company anticipates data releases for INHBE and ALK7 related to obesity, with additional ALK7 data expected in the first half of 2026, approximately 6 months behind INHBE in dosing [3]